enGene Q3 net loss $14.1M; cash $257.7M; LEGEND data expected Sept 2024

enGene Therapeutics Inc.

2024-Q3 EPS reported $1.12

Net loss $14.1M ($0.32/share) vs $6.0M prior year; operating expenses $16.8M (up from $6.2M).
Cash and equivalents $257.7M; expects runway into 2027.
Preliminary LEGEND study data (BCG-unresponsive NMIBC) due by end of September 2024.
Ron Cooper appointed CEO and board member; Dr. Raj Pruthi promoted to CMO in July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.